DIA415.36+6.58 1.61%
SPX5,638.94+117.42 2.13%
IXIC17,754.09+451.07 2.61%

Investors Hit the Jackpot! 8 Micro, Small, and Mid-Cap Stocks That Went Through the Roof

Barchart·03/06/2025 16:08:15
Listen to the news

The broader stock market faced renewed selling pressure today, with major indices experiencing sharp declines. The Dow Jones Industrial Average plunged 500 points, extending its recent losing streak as investors remained cautious amid economic uncertainties. Meanwhile, the Nasdaq Composite slid, weighed down by AI-related concerns and disappointing earnings from key tech firms. While most stocks struggled, a few companies saw unusual one-day gains fueled by breaking news, acquisitions, and record earnings. In this article, we explore the 8 micro, small, and mid-cap stocks that went through the roof and what drove their impressive one-day performance.

Read Next: This Might Be the Most Undervalued Biotech Stock on the Market Today, Here’s Why

Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.

8. MP Materials (NYSE:MP)

  • 1-Day Gain as of March 6: 14.30%
  • Market Cap as of March 6: $4.19 Billion

MP Materials is a leading producer of rare earth materials, primarily neodymium and praseodymium, which are essential for electric vehicles, wind turbines, and defense applications. The company operates the Mountain Pass mine in California, the only large-scale rare earth mining operation in North America.

Trump’s Announcement: President Donald Trump has announced to take historic action to dramatically expand production of critical minerals and rare earths in the USA in his address to Congress.

Expected Benefit from New Policy: As the largest rare earths miner in the US, MP Materials is expected to benefit from the new policy.

Recent Achievements: The company reported a record production of rare earth oxides, with 45,455 metric tons of REO in concentrate in 2024.

Supply Agreements: MP Materials has signed supply agreements with major global automakers and the US Department of Defense.

Government Subsidy: The company recently received a $58.5 million tax credit from the government to accelerate its production ramp, which makes it logical to assume that MP will benefit from the new policy.

Popular Conversations From the Yahoo! Finance Community:

7. SiTime (NASDAQ:SITM)

  • 1-Day Gain as of March 6: 19.53%
  • Market Cap as of March 6: $4.30 Billion

SiTime Corporation is a leading provider of MEMS (Micro-Electro-Mechanical Systems) timing solutions that replace traditional quartz crystal oscillators. Its technology enables higher precision and reliability in applications such as 5G, automotive, and IoT devices.

Inclusion in iPhone 16e: A device teardown by TechInsights revealed that SiTime’s timer chips are used in the new iPhone 16e, and indicate a significant partnership with Apple.

Confirmation by CEO: SiTime’s CEO, Rajesh Vashist, confirmed the arrangement during a Morgan Stanley event, stating that the company “has a couple of chips” in the iPhone 16e.

Potential Market Opportunity: SiTime’s precision-timing technology has a huge potential market, which can be used in various devices, including cars and military navigation systems.

Apple’s Reliance on SiTime: According to SiTime’s annual report, Apple accounts for about 22% of the company’s revenue, making it the largest end customer.

Popular Conversations From the Yahoo! Finance Community:

6. Tonix Pharmaceuticals (NASDAQ:TNXP)

  • 1-Day Gain as of March 6: 40.51%
  • Market Cap as of March 6: $61.27 Million

Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, infectious diseases, and rare conditions. Its pipeline includes potential therapies for fibromyalgia, PTSD, and long COVID.

Positive Data Presentation: Tonix Pharmaceuticals has presented data and analyses of TNX-102 SL treatment effects on fibromyalgia at the 7th International Congress on Controversies in Fibromyalgia, which showed statistically significant improvement in reducing fibromyalgia pain in two double-blind randomized Phase 3 studies.

Upcoming FDA Decision: The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on marketing authorization for TNX-102 SL, which could lead to the approval of the first new treatment option for fibromyalgia patients in 15 years.

Potential For First-In-Class Treatment: If approved, TNX-102 SL would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia, providing a new treatment option for patients with limited effective treatments.

Contract With the U.S. Department of Defense: Tonix Pharmaceuticals recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, a small molecule broad-spectrum antiviral agent, which demonstrates the company’s potential for partnerships and collaborations.

Popular Conversations From the Yahoo! Finance Community:

5. CarParts.com (NASDAQ:PRTS)

  • 1-Day Gain as of March 6: 40.72%
  • Market Cap as of March 6: $71.18 Million

CarParts.com is an e-commerce platform specializing in aftermarket auto parts and accessories. The company leverages data-driven inventory management and a direct-to-consumer model to provide cost-effective car repair solutions.

Exploration of Strategic Alternatives: The company has announced that it is exploring strategic alternatives to maximize shareholder value, including a possible sale of the company.

Possible Sale Of The Company: The mention of a possible sale of the company sparked speculation about a potential takeover or acquisition, which can often lead to a significant increase in stock price.

Inbound Strategic Inquiries: CarParts.com has received inbound strategic inquiries, which suggests that there is interest in the company from potential buyers.

Engagement of Financial and Legal Advisors: The appointment of Craig-Hallum Capital Group LLC as financial advisor and Wilson Sonsini Goodrich & Rosati as legal counsel indicates that the company is taking a serious and professional approach to exploring strategic alternatives.

Popular Conversations From the Yahoo! Finance Community:

Read Now: Why This Electric Vehicle Market Player’s Proprietary Battery-Swapping Technology is a Game-Changer

Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.

4. ChromaDex (NASDAQ:CDXC)

  • 1-Day Gain as of March 6: 52.68%
  • Market Cap as of March 6: $664.77 Million

ChromaDex is a bioscience company known for its proprietary ingredient, Niagen, a patented form of nicotinamide riboside (NR) that supports cellular health and aging research. The company partners with major health brands to commercialize its anti-aging supplements.

Record Revenue Growth: ChromaDex reported a 37% year-over-year increase in revenue, reaching $29.1 million in Q4 2024, surpassing the consensus estimate by 7.47%. The company’s gross margin improved by 150 basis points to 62.5%.

Net Income Turnaround: The company achieved a net income of $7.2 million in Q4 2024, contributing to a full−year net income of $8.6 million, a significant turnaround from a net loss in 2023. The company reported quarterly earnings of $0.03 per share, beating the consensus estimate of $0.02 per share by 50%

Strong E-commerce Sales: The e-commerce channel experienced robust growth with net sales of $17.3 million, a 30% increase year-over-year.

NIAGEN Ingredient Sales Growth: The NIAGEN ingredients business saw a 96% increase in net sales year-over-year, driven by strong demand for both food-grade and pharmaceutical-grade products.

Strong Financial Health: ChromaDex ended the year with $44.7 million in cash and no debt, indicating strong financial health.

Popular Conversations From the Yahoo! Finance Community:

3. ARB IOT (NASDAQ:ARBB)

  • 1-Day Gain as of March 6: 60.88%
  • Market Cap as of March 6: $22.12 Million

ARB IOT is a Malaysian technology company that provides IoT (Internet of Things) solutions for smart buildings, energy management, and industrial automation.

Major Order Win: ARB IOT has secured a significant order with Gajah Kapitalan worth approximately $45 million for its AI data center server solution, which is a substantial revenue boost.

Validation of ARB IOT’s Technology: The order from GKSB validates ARB IOT’s AI server solutions and its ability to deliver high-performance and cost-effective products. The partnership also provides a platform for future collaborations and growth opportunities, both in Malaysia and beyond.

Positive Guidance: The company’s CEO, Dato’ Sri Liew Kok Leong, expressed confidence in the company’s ability to deliver significant cost savings and operational efficiencies to customers, which suggests a positive outlook for the company’s future financial performance.

Popular Conversations From the Yahoo! Finance Community:

2. Chimerix (NASDAQ:CMRX)

  • 1-Day Gain as of March 6: 70.56%
  • Market Cap as of March 6: $760.86 Million

Chimerix is a biopharmaceutical company developing antiviral and oncology treatments. Its pipeline includes ONC201, a promising therapy for brain tumors, and brincidofovir, an antiviral treatment for smallpox and other viral infections.

Potential Acquisition: Chimerix’s stock has surged by almost 70% due to the announcement of a definitive agreement with Jazz to acquire the company for approximately $935 million. The acquisition is expected to close in Q2 2025, pending approval.

Significant Premium: Jazz Pharmaceuticals is offering $8.55 per share, a 72.4% premium to Chimerix’s closing price of $4.96 on March 4.

All-cash Deal: The acquisition is an all-cash transaction and provides certainty for Chimerix shareholders and eliminates any potential risks associated with a stock-based transaction.

Potential Value of Dordaviprone: Dordaviprone, Chimerix’s lead investigational candidate, has significant potential value as a treatment for a rare and aggressive brain tumor. Dordaviprone is currently under review by the FDA.

Popular Conversations From the Yahoo! Finance Community:

1. Visionary Holdings (NASDAQ:GV)

  • 1-Day Gain as of March 6: 186.43%
  • Market Cap as of March 6: $16.00 Million

Visionary Holdings is a China-based company specializing in private education services. The company operates international schools and vocational training programs, benefiting from China’s growing demand for high-quality education services.

New Energy Vehicle Project: Visionary Holdings has entered the new energy vehicle market with a focus on developing a range of new energy vehicles, including compact sedans, luxury SUVs, and pickup trucks.

Financing Deal: Visionary Holdings has secured a $1 billion financing consent letter from the Alfardan Group of Qatar, which will be used to drive the development of its new energy vehicle project, PEGASUS. 

Global Expansion: Visionary Holdings’s plans to expand into the European and American markets and to cooperate with internationally renowned enterprises.

Strong Product Pipeline: The company has initially launched two core vehicle models and plans to introduce more models in the future.

Technological Advancements: Visionar Holdings is focusing on developing advanced technologies, such as high-energy-density solid-state battery technology, to stay ahead of the competition.

Popular Conversations From the Yahoo! Finance Community:

Conclusion

Despite the recent turmoil in the US stock market, several stocks have bucked the trend and posted notable gains. To capitalize on these opportunities while minimizing risk, it’s essential for investors to understand industry developments, and company-specific factors can help investors identify the key catalysts driving the performance of these smaller-cap stocks. These stocks, often overlooked in favor of their larger counterparts, can provide significant growth opportunities for those willing to delve deeper.

Also Read: Why This Low Float Biotech Stock Looks Ripe for Another Big Breakout

Our email list eats first! Get exclusive alerts on explosive stock picks like AST SpaceMobile (NASDAQ: ASTS), which shot up +533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.

Join the Discussion in the WVC Facebook Investor Group

Do you have a stock tip or news story suggestion? Please email us at Invest@WealthyVC.com.

Disclaimer: Wealthy VC does not hold a position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.

The post Investors Hit the Jackpot! 8 Micro, Small, and Mid-Cap Stocks That Went Through the Roof appeared first on Wealthy Venture Capitalist.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.